Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: Results from the population-based PROFILES registry

Are chemotherapy-associated symptoms underestimated? A view beyond common toxicity criteria

“…In addition, we investigated the incidence and severity of the common side effect CIPN, and reported that CIPN was still often experienced by CRC survivors up to 11 years after diagnosis with a negative influence on their QoL [10,12]. Similar results were reported up to 12 years after the end of treatment in women with ovarian cancer who received chemotherapy [13]. The side effect that is most neglected is alopecia [14].…”

Effect of Chemotherapy on Health-Related Quality of Life among Early-Stage Ovarian Cancer Survivors: A Study from the Population-Based Profiles Registry

“…Equally, in our own prior study that included all stages of ovarian cancer, we observed that symptoms of neuropathy were experienced by 51% of women and seriously affected their hrqol 15 . Interesting data from Mirabeau-Beale et al 19 showed a significant difference in fear of cancer recurrence between early-stage and advanced-stage survivors.…”

“…Chemotherapy-induced peripheral neuropathy is reported in 38% of patients treated with multiple chemotherapeutic regimens 14 . We observed neuropathy symptoms in 51% of survivors with ovarian cancer of all stages, even up to 12 years after the end of treatment 15 . Cognitive impairment is a commonly reported late-term side effect of chemotherapy that can interfere with a cancer survivor's ability to attain professional and social goals 14 .…”

Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer

“…Treatment in accordance with guidelines led to significantly improved survival outcomes. The fact that 84% of the patients in our study were treated according to Dutch guidelines indicates that the GOCS provides high-quality care for patients with early-stage EOC in the Netherlands, but long-term complications of chemotherapy-induced neuropathy should also be considered and balanced especially for patients with low- and intermediate risk [8,9,28]. …”

“…Yet, it remains uncertain whether women with low- and intermediate-risk early-stage disease will benefit as much from adjuvant chemotherapy as women with high-risk disease. Recent data demonstrated that even 12 years after the end of chemotherapy neuropathy symptoms were experienced by 51% of the patients with ovarian cancer [9]. Hence, as mentioned by the authors in the Cochrane review, adjuvant chemotherapy in women with lower-risk EOC should be individualized.…”